ProtoKinetix, Incorporated (PKTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProtoKinetix, Incorporated (PKTX) trades at $0.01 with AI Score 42/100 (Grade C). ProtoKinetix, Incorporated is a biotechnology company focused on the research and development of anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). Market cap: $2.55M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for PKTX: PKTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PKTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PKTX: the 1 perspectives are evenly split.
How is this calculated? →ProtoKinetix, Incorporated (PKTX) Healthcare & Pipeline Overview
ProtoKinetix, Incorporated is a research and development stage biotechnology firm specializing in anti-freeze and anti-aging glycoproteins for healthcare applications, particularly dry-eye disease treatment. Operating in the competitive biotechnology sector, the company collaborates with the University of British Columbia to advance its research and development efforts.
What Is the Investment Thesis for PKTX?
ProtoKinetix, Incorporated presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on AFGPs and AAGPs offers potential in the healthcare sector, particularly for dry-eye disease treatments. However, the company's negative profit margin of -772.8% and negative gross margin of -28.4% indicate significant financial challenges. Key value drivers include successful clinical trials and commercialization of its AAGP technology. Growth catalysts depend on securing additional funding and partnerships. Potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the inherent uncertainty of biotechnology research.
Based on FMP financials and quantitative analysis
PKTX Key Highlights
- Market capitalization of $2.55M reflects the company's early stage and speculative nature.
- P/E ratio of -7.03 indicates the company is not currently profitable.
- Profit margin of -772.8% highlights significant losses relative to revenue.
- Gross margin of -28.4% suggests challenges in controlling production costs.
- Beta of 0.52 indicates lower volatility compared to the overall market.
Who Are PKTX's Competitors?
PKTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARUXF Acrux Limited | $0.02 | -0.00% | $6.78M | 46 |
| IBOGF Universal Ibogaine Inc. | $0.03 | -3.01% | $8.07M | 47 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PKTX's Key Strengths?
- Proprietary AAGP/AFGP technology.
- Collaboration with the University of British Columbia.
- Potential for novel dry-eye disease treatment.
- Focus on a growing market segment within healthcare.
What Are PKTX's Weaknesses?
- Research and development stage company with no current revenue.
- High operating losses and negative profit margin.
- Reliance on external funding for continued operations.
- OTC market listing indicates higher risk and lower liquidity.
What Could Drive PKTX Stock Higher?
- Results from ongoing research collaboration with the University of British Columbia could provide positive data and validate the company's technology.
- Potential for securing additional funding through grants, private placements, or partnerships to support research and development efforts.
- Progress in preclinical or clinical trials for dry-eye disease treatment could attract investor attention and increase the company's valuation.
- Continued efforts to expand the intellectual property portfolio and secure patents for AAGP technology.
- Exploration of new applications for AAGP technology beyond dry-eye disease, such as wound healing or cosmetics.
What Are the Key Risks for PKTX?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding could halt research and development activities and threaten the company's survival.
- Negative results from clinical trials could undermine the company's prospects and lead to a decline in its stock price.
- Competition from established pharmaceutical companies with greater resources and expertise.
- Regulatory hurdles and lengthy approval processes for new drug therapies.
- The inherent uncertainty of research and development outcomes in the biotechnology industry.
What Are the Growth Opportunities for PKTX?
- Development of Dry-Eye Disease Treatment: ProtoKinetix is focused on developing AAGP to treat dry-eye diseases. The global dry eye disease market is projected to reach $6.4 billion by 2028, growing at a CAGR of 5.3% from 2021. Successful development and commercialization of a dry-eye treatment could provide significant revenue potential for ProtoKinetix. The timeline for this growth opportunity depends on clinical trial results and regulatory approvals.
- Expansion of AAGP Applications: Beyond dry-eye disease, ProtoKinetix can explore other potential applications of its AAGP technology in areas such as wound healing, cosmetics, and regenerative medicine. Each of these areas represents a multi-billion dollar market. This expansion would require further research and development, but could significantly broaden the company's revenue streams.
- Strategic Partnerships: ProtoKinetix can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its AAGP technology. These partnerships could provide funding, expertise, and access to established distribution channels. The timeline for securing partnerships is uncertain, but it could significantly impact the company's growth trajectory.
- Intellectual Property Protection: Strengthening and expanding its intellectual property portfolio is crucial for ProtoKinetix. Securing patents for its AAGP technology and its various applications will provide a competitive advantage and protect its market position. The ongoing effort to maintain and expand its patent portfolio is a continuous growth opportunity.
- Collaboration with the University of British Columbia: ProtoKinetix has a collaboration research agreement with the University of British Columbia. This collaboration provides access to research expertise and resources, potentially accelerating the development of its AAGP technology. Continued collaboration and successful research outcomes could lead to new discoveries and commercial opportunities.
What Opportunities Does PKTX Have?
- Successful clinical trials and regulatory approval for dry-eye treatment.
- Expansion of AAGP applications to other therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Securing additional funding through grants or private placements.
What Threats Does PKTX Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Failure to secure additional funding.
- Uncertainty of research and development outcomes.
What Are PKTX's Competitive Advantages?
- Proprietary glycoprotein technology (AFGPs and AAGPs).
- Collaboration research agreement with the University of British Columbia.
- Potential for novel treatments in the dry-eye disease market.
What Does PKTX Do?
ProtoKinetix, Incorporated, established in 1999 and based in Marietta, Ohio, is a biotechnology company in the research and development phase. Originally incorporated as RJV Network, Inc., the company rebranded in July 2003 to reflect its focus on scientific medical research of anti-freeze glycoproteins (AFGPs), also known as anti-aging glycoproteins (AAGPs). These glycoproteins are being explored for their potential commercial applications, primarily in healthcare solutions. The company's core focus is on developing AAGP-based treatments, with a specific emphasis on addressing dry-eye diseases. ProtoKinetix operates through research collaborations, including an agreement with the University of British Columbia, to further its scientific advancements. ProtoKinetix is dedicated to advancing its research and development efforts in the biotechnology space, specifically targeting healthcare solutions through its unique glycoprotein technology.
What Products and Services Does PKTX Offer?
- Conducts scientific medical research on anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs).
- Develops AFGPs for commercial applications in health care solutions.
- Focuses on developing AAGP to treat dry-eye diseases.
- Collaborates with the University of British Columbia for research purposes.
- Aims to create innovative healthcare solutions based on its glycoprotein technology.
How Does PKTX Make Money?
- Focuses on research and development of AAGPs and AFGPs.
- Seeks to commercialize its glycoprotein technology through healthcare applications.
- Explores partnerships and collaborations to fund and accelerate development.
What Industry Does PKTX Operate In?
ProtoKinetix operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for dry-eye disease treatments is growing, driven by an aging population and increased screen time. Competitors include both established pharmaceutical companies and other biotechnology firms developing novel therapies. ProtoKinetix's success depends on its ability to differentiate its AAGP technology and navigate the complex regulatory landscape.
Who Are PKTX's Key Customers?
- Future patients suffering from dry-eye diseases.
- Potential pharmaceutical partners interested in licensing or acquiring their technology.
- Healthcare providers seeking innovative treatment options.
How ProtoKinetix, Incorporated Is Valued
ProtoKinetix, Incorporated carries a market capitalization of $2.55M, placing it in the micro-cap category. Relative to its peer group, PKTX's quantitative score of 42/100 is below the peer average of 65/100.
Company Profile
ProtoKinetix, Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Marietta, US. The company is led by CEO Michael Richard Guzzetta. PKTX has traded publicly since 2002.
Key Financial Metrics
Return on assets is -78.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
ProtoKinetix, Incorporated's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PKTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary AAGP/AFGP technology.
- Collaboration with the University of British Columbia.
- Potential for novel dry-eye disease treatment.
- Focus on a growing market segment within healthcare.
Bear Case
- Research and development stage company with no current revenue.
- High operating losses and negative profit margin.
- Reliance on external funding for continued operations.
- OTC market listing indicates higher risk and lower liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PKTX Latest News
No recent news available for PKTX.
PKTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PKTX.
Price Targets
Wall Street price target analysis for PKTX.
PKTX MoonshotScore
What does this score mean?
The MoonshotScore rates PKTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Richard Guzzetta
CEO
Michael Richard Guzzetta serves as the CEO of ProtoKinetix, Incorporated. Information regarding his detailed career history, education, and previous roles is not available in the provided data. His leadership is focused on guiding the company's research and development efforts in the biotechnology sector, specifically related to anti-freeze and anti-aging glycoproteins.
Track Record: Due to limited information, it's challenging to assess Michael Richard Guzzetta's specific achievements and strategic decisions at ProtoKinetix. His tenure involves navigating the challenges of a research and development stage company, focusing on scientific advancements and seeking potential commercial applications for the company's technology.
PKTX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ProtoKinetix may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited operating history, are thinly traded, or may be experiencing financial difficulties. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Difficulty in obtaining reliable financial information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property portfolio and competitive landscape.
- Evaluate the company's funding sources and cash runway.
- Understand the company's business model and revenue potential.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Collaboration research agreement with the University of British Columbia.
- Focus on scientific medical research of AFGPs/AAGPs.
- Efforts to develop treatments for dry-eye diseases.
- Company has been in operation since 1999.
What Investors Ask About ProtoKinetix, Incorporated (PKTX) — Healthcare
What does ProtoKinetix, Incorporated do?
ProtoKinetix, Incorporated is a biotechnology company focused on the research and development of anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). The company aims to develop healthcare solutions using its proprietary glycoprotein technology, with a primary focus on treating dry-eye diseases. ProtoKinetix collaborates with the University of British Columbia to advance its research and explore various commercial applications for its technology within the healthcare sector. The company is currently in the research and development stage and does not generate revenue from product sales.
What do analysts say about PKTX stock?
As a thinly traded OTC stock with limited analyst coverage, there is no readily available analyst consensus on PKTX. The company's valuation is speculative, driven by the potential of its AAGP technology. Investors should carefully consider the risks associated with investing in early-stage biotechnology companies, including the uncertainty of research outcomes, regulatory hurdles, and the need for additional funding. Due to the OTC listing, information on the company may be limited, and investors should conduct thorough due diligence before investing.
What are the main risks for PKTX?
The primary risks for ProtoKinetix include its dependence on securing additional funding to continue its research and development activities. Failure to obtain funding could significantly impede its progress. Clinical trial failures or regulatory setbacks would also negatively impact the company. Competition from larger, more established pharmaceutical companies poses a significant threat. Additionally, as an OTC-listed stock, PKTX is subject to liquidity risk, price volatility, and limited regulatory oversight, making it a high-risk investment.
What are the key factors to evaluate for PKTX?
ProtoKinetix, Incorporated (PKTX) holds an AI score of 42/100 (low). Not financial advice.
How frequently does PKTX data refresh on this page?
PKTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PKTX's recent stock price performance?
ProtoKinetix, Incorporated (PKTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AAGP/AFGP technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PKTX overvalued or undervalued right now?
Valuing ProtoKinetix, Incorporated (PKTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PKTX?
Before investing in ProtoKinetix, Incorporated (PKTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may not be fully up-to-date.
- AI analysis pending for PKTX.